Navigation Links
Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer

Scientists to Present Data on Innovative Oncology Compounds at the American Association for Cancer Research Annual Meeting

ABBOTT PARK, Ill., April 13, 2007 /PRNewswire-FirstCall/ -- For decades, scientists have looked for new therapies that target cancer. Researchers now know that cancer cells have several unique characteristics -- they require new blood vessels to deliver oxygen and nutrients (angiogenesis), they grow uncontrollably (proliferation), they travel throughout the body (metastasis), and they escape programmed cell death, a natural process by which the body rids itself of damaged or unwanted cells (apoptosis). Robust preclinical data shows that several compounds in Abbott's oncology pipeline interfere with these vital processes. Data on two of these compounds will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-18 in Los Angeles.

During the meeting, scientists from independent academic institutions and Abbott will present data on Abbott's Bcl-2 family protein inhibitor (ABT-263). This compound, currently in early clinical development, corrects defects in cancer cells that allow them to escape programmed cell death. They will also present data on an investigational PARP inhibitor (ABT-888) that enhances the effectiveness of common cancer therapies that damage DNA in cancer cells.

    Presentation highlights include:


    ABT-263

    --  "ABT-263:  An orally bioavailable Bcl-2 family protein inhibitor"

        [Oral presentation, Sunday, April 15, 1 p.m., Hall A]

    --  "Pediatric preclinical testing program (PPTP) evaluation of the Bcl-2

         inhibitor ABT-263"

        [Oral presentation, Tuesday, April 17, 3:55 p.m., Room 404 A-B]


    ABT-888

    --  "The poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888 potentiates

         the antitumor activity of temozolomide in the B16F10 syngeneic

         melanoma model: Correlation with pharmacokinetic levels and a

  
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. NIEHS Researchers Identify Enzyme Critical in DNA Replication
11. Stanford Researchers Find Brain Pathway of Depression in Rats
Post Your Comments:
(Date:7/23/2014)... Research and Markets has announced ... and Surgical) Markets Worldwide 2014" report to their ... The purpose of this report is to analyze ... and Surgical) Gloves. The report discusses key players and ... Topics covered include product definitions, strategies, competitive analysis, ...
(Date:7/23/2014)... , July 23, 2014  The management team ... ) will hold a conference call on July ... second quarter ended June 30, 2014.  The call ... 2014Time: , 8:30 am EDTDial-in numbers: , Toll ... (412) 317-0790Webcast (live & archive): , www.columbialabs.com ...
(Date:7/23/2014)... July 23, 2014  Silk Road Medical, Inc., ... treatment of intra- and extra-cranial cerebrovascular disease, announced ... to the position of Chief Technology Officer.  ... company,s Research and Development efforts across its family ... Prior to joining Silk Road Medical, Michael ...
Breaking Medicine Technology:Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 2Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 3Disposable Medical Gloves (Exam and Surgical) Markets Worldwide 2014 4Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3
... , , SANTA MONICA, ... the winners of the ,Give Thanks for Loved Ones, Brain Health ... the symptoms of dementia and Alzheimer,s disease. All five winners will ... to help seniors preserve their brain health and the most widely ...
... , , KNOXVILLE, Tenn., Dec. 15 ... attention with their revolutionary new technology for a simple blood ... the success of its pre-clinical trials for the ColoMarker(TM) assay, ... all aspects of its use. Via an inexpensive blood ...
Cached Medicine Technology:5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer 2
(Date:7/23/2014)... 23, 2014 Four hospitals affiliated with ... in the latest ranking of the country’s best hospitals ... Released online today and slated for publication in August, ... General Hospital (AGH), Forbes Hospital, Saint Vincent Hospital and ... multiple clinical specialties. , “There is no ...
(Date:7/23/2014)... WEDNESDAY, July 23, 2014 (HealthDay News) --,Jealousy may not ... showing dogs can get downright possessive when it comes ... owners showed affection toward what was actually a stuffed ... snapping or pushing the stuffed dog aside, report researchers ... This jealous streak only surfaced when owners were attending ...
(Date:7/23/2014)... In a massive effort to catalog the ... at Dana-Farber Cancer Institute, have identified four subtypes ... molecular abnormalities. They say the new classification promises ... for the third-leading cancer killer worldwide. , In ... The Cancer Genome Atlas Research Network said they ...
(Date:7/23/2014)... Texas Physical Therapy Specialists (TexPTS) is ... Westlake, Westgate, Liberty Hill, Parmer, Balcones, and Georgetown clinics ... Orthopaedic Certified Specialist (OCS) or Sports ... DPT, OCS, Tony Lauretta, PT, DPT, OCS, Jason Brown, ... Leech, PT, DPT, OCS, and Mary Grimberg, PT, DPT, ...
(Date:7/23/2014)... 2014 A therapy combining salmon fibrin injections into ... into the brain restored voluntary motor function impaired by ... Center have found. , In a study on rodents, ... turning back the developmental clock in a molecular pathway ... and providing a scaffold so that neuronal axons at ...
Breaking Medicine News(10 mins):Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3Health News:Dogs Can Get Jealous, Too 2Health News:New view of stomach cancer could hasten better therapies 2Health News:New view of stomach cancer could hasten better therapies 3Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2
... it time for all community-based doctors to turn to e-prescribing ... According to Rainu Kaushal and colleagues from the Weill Cornell ... prescribing errors up to seven-fold. Their study of ... in the Journal of General Internal Medicine , published ...
... ... renowned publication, The Leading Physicians of the World. Dr. Sood will be representing the ... dermatologists from all over the globe. , ... New York, NY (PRWEB) February 22, 2010 -- As owner of Harper Dermatology ...
... ... ... ... ...
... ... ... ... ...
... proven to enhance bone density and reduce fracture incidence ... increase risk of atypical fractures of the femur when ... research presented today at the 2010 Annual Meeting of ... Bisphosphonates are designed to slow or stop the ...
... , ... best selling author David S. Linthicum kicks off the Webinar series with Best Practices in ... ... of the Leveraging Cloud Computing Within the Modern Data Center webinar series. These media ...
Cached Medicine News:Health News:Physicians click their way to better prescriptions 2Health News:Neuro Drinks Provide Sparkling Refreshment on a Star-Studded Evening at the 18th Annual Academy Awards(R) Viewing Party Hosted by the Elton John AIDS Foundation 2Health News:Neuro Drinks Provide Sparkling Refreshment on a Star-Studded Evening at the 18th Annual Academy Awards(R) Viewing Party Hosted by the Elton John AIDS Foundation 3Health News:Neuro Drinks Provide Sparkling Refreshment on a Star-Studded Evening at the 18th Annual Academy Awards(R) Viewing Party Hosted by the Elton John AIDS Foundation 4Health News:Neuro Drinks Provide Sparkling Refreshment on a Star-Studded Evening at the 18th Annual Academy Awards(R) Viewing Party Hosted by the Elton John AIDS Foundation 5Health News:Kimberly-Clark Introduces Kleenex Hand Towels 2Health News:Kimberly-Clark Introduces Kleenex Hand Towels 3Health News:Kimberly-Clark Introduces Kleenex Hand Towels 4Health News:Kimberly-Clark Introduces Kleenex Hand Towels 5Health News:Kimberly-Clark Introduces Kleenex Hand Towels 6Health News:Quantity vs. quality: Long-term use of bone-building osteoporosis drugs 2Health News:Quantity vs. quality: Long-term use of bone-building osteoporosis drugs 3Health News:Bick Group Launches Leveraging Cloud Computing Within the Modern Data Center Webinar Series 2
... achieves a secure clot, targeted to the ... hemostasis is needed, when control of bleeding ... and cautery, is ineffective or impractical., CROSSEAL* ... of human Biologically Active Component (BAC) and ...
Mastisol Liquid Adhesive is a clear, non-irritating, and non-water-soluble liquid adhesive that secures the most difficult dressings for an extended period of time. Mastisol is 7 to 10 times stickier...
... Indermil® tissue adhesive is indicated for ... laparoscopic incisions, and trauma-induced lacerations in areas ... thoroughly-cleansed, and have easily approximated skin edges. ... tissue adhesive may act as a barrier ...
The first Ethyl-2-Cyanoacrylate tissue adhesive in a tube that is more economical than sutures!...
Medicine Products: